BAYRY News and Press, Bayer AG ADR From 11/11/22

A committee of the European Medicines Agency (EMA) recommended the expanded approval of Regeneron Pharmaceuticals ( NASDAQ: REGN ) and Bayer's ( OTCPK:BAYZF ) ( OTCPK:BAYRY ) Eylea to treat preterm infants with retinopathy of prematurity (ROP). ROP is...

Summary Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Markets remain very volatile following record inflation readings paired with an aggressive Fed and negative consumer sentiment. US-China relations remain tense but so far don...

Summary Bayer delivered a better than expected September quarter, beating analyst consensus with regards to both sales and earnings. The strong results highlight once again that market sentiment towards Bayer's business initiatives - most notably the agriculture segment - is laggi...

Bayer AG (BAYZF) Q3 2022 Earnings Conference Call November 08, 2022, 08:00 ET Company Participants Oliver Maier - Head, IR Werner Baumann - Chairman, CEO & Chief Sustainability Officer Wolfgang Nickl - CFO Heiko Schipper - President, Consumer Health Divis...

The following slide deck was published by Bayer Aktiengesellschaft in conjunction with their 2022 Q3 earnings call. For further details see: Bayer Aktiengesellschaft 2022 Q3 - Results - Earnings Call Presentation

Bayer's ( OTCPK:BAYRY ) ( OTCPK:BAYZF ) Q3 sales were driven by its Crop Sciences business, offsetting the decline in sale of its top selling pharma product Xarelto. The German conglomerate confirmed its FY22 outlook. Bayer's core EPS grew +7.6% Y/Y to ...

Bayer ( OTCPK:BAYZF ) ( OTCPK:BAYRY ) is returning the rights to fesomersen, a phase 2 candidate for patients with end-stage renal disease (ESRD) on hemodialysis, back to Ionis Pharmaceuticals ( NASDAQ: IONS ). Ionis ( IONS ) said it is working on finding a new...

Summary International markets faced headwinds as slowing economic growth and hawkish monetary policy by central banks stoked investor fears of a possible global recession. The Strategy outperformed its benchmark, as high-quality stocks in the materials and industrials sectors over...

Summary Subscribers to my Dividend Dogcatcher Marketplace (behind the SA paywall) know my Viital portfolio (#VII) stocks are “selected based-on gains, yield, momentum, price-upside, dividend-history, analyst-interest, special-market qualities, and dividend-safety.”. ...

Bayer ( OTCPK:BAYZF ) ( OTCPK:BAYRY ) on Wednesday said Canada's drug regulator had approved its Kerendia medicine as an adjunct to standard of care for the treatment of chronic kidney disease (CKD) and type 2 diabetes (T2D). An adjunct is an additional treatment that is u...